LAS VEGAS, Feb. 23, 2026 (GLOBE NEWSWIRE) -- VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced a major advancement in its next-generation robotic systems that enhances reliability, safety, and operational continuity for the Company’s network of automated retail hubs. Every robotic component within the VenHub ecosystem, including the robotic arms, dynamic bins, and intelligent refrigerators, now feature advanced self-diagnosti ...

Core Viewpoint - BrainsWay Ltd. is a leader in noninvasive brain stimulation technologies, focusing on advancing neuroscience through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, which has received FDA clearance for multiple mental health disorders [2]. Group 1: Company Overview - BrainsWay is recognized for its advanced neurostimulation treatments aimed at mental health disorders, with a commitment to improving health and transforming lives [2]. - The company has achieved FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [2]. - Founded in 2003, BrainsWay operates in the United States and Israel, with ongoing clinical trials for Deep TMS in various psychiatric, neurological, and addiction disorders [2]. Group 2: Upcoming Events - Management from BrainsWay will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on February 26, 2026, in New York [1].

ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences. Oppenheimer 36th Annual H ...

Vancouver, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1; OTC:TEBAF) is pleased to announce further high-grade assay results from the Phase III drill campaign at the Cumavici Ridge polymetallic, epithermal vein zone within its principal Viogor-Zanik project in eastern Bosnia and Herzegovina. Highlights Drillhole CMV25004 intersected 636 g/t Ag Eq. over 4.3 m including: 1,757 g/t Ag Eq over 0.8 m1,319 g/t Ag Eq over 0.4 m ...

Core Insights - BioVie Inc. is hosting a webinar on March 4, 2026, to discuss its investigational drug candidate bezisterim (NE3107) and its orphan drug candidate BIV201 [1][2][3] Group 1: Drug Development - Bezisterim (NE3107) is a first-in-class, orally available small molecule targeting inflammation and insulin resistance, which are key drivers of Alzheimer's, Parkinson's, and Long COVID, showing promising results in improving cognition, motor function, and reducing neuroinflammation [2][6] - BIV201 is a continuous infusion treatment of terlipressin for patients with cirrhosis and ascites, which has received FDA Orphan and Fast Track designations, and is set to enter a Phase 3 trial [3][7] Group 2: Market Potential - BioVie is positioned to create significant value with multiple clinical programs advancing into late-stage development, supported by strong safety data and multi-billion-dollar market opportunities [3] - The company aims to address life-threatening complications in liver disease with no FDA-approved therapies currently available [3][7]

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: TD Cowen 46th Annual Healthcare ConferenceFireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MABarclays 28th Annual Global Healthcare ConferenceFireside Chat on Tuesday, March 10 at 10:30 a. ...

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University fo ...

BLFC Sensory Room Image of future sensory Collegium Pharmaceutical Sensory Room for BLFC home matches Scoreboard for BLFC Scoreboard at BLFC Matches at White Stadium with Collegium Branding BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are w ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan” or the “Company”) today announced that its Board of Directors has authorized a share repurchase program of up to $10 million of the Company’s outstanding common stock through December 31, 2027. The authorization reflects the Company’s continued focus on disciplined capital allocation. It follows the February 2026 completion of its $15 million tender offer, which reduced the Company’s common stock issued and ou ...

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infus ...